波兰甲状腺微小乳头状癌患者中BRAFV600E与TERT突变共存的显著性:基于430例的回顾性队列研究
该回顾性队列研究纳入2001—2020年单中心诊断的430例甲状腺微小乳头状癌(PTMC)患者,分析BRAFV600E与TERT启动子突变共存对临床病理特征、治疗反应及结局的影响;
要点
- 共存突变组与无突变组在风险分层、治疗反应、临床病程及最终状态无显著差异。
- 无论分子背景如何,PTMC患者总体治疗反应优秀,多数可获得长期无病生存。
核心结论
- 无论PTMC的分子背景如何,总体治疗反应优秀,多数患者可获得长期无病生存。
研究设计与样本
- 回顾性分析2001—2020年单中心诊断的430例PTMC病例,全部经组织病理学评估,并基于肿瘤组织块提取DNA进行BRAFV600E和TERT启动子分析。
主要发现
- 共存BRAFV600E与TERT热点突变组与无任何上述突变组在风险分层、原发治疗反应、临床病程及最终疾病状态方面均无显著差异。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: The incidence of papillary thyroid cancer is increasing worldwide due to more frequent pathological detection of papillary thyroid microcarcinomas (PTMC), which are cancers measuring 1 cm or less in diameter. In rare cases, the course of PTMC can be aggressive, with an increased risk of recurrence/persistent disease. The aim of this study of Polish patients diagnosed with PTMC was to assess the impact of concomitant B-type Raf kinas-activating mutation in codon 600 of exon 15 (BRAFV600E) and telomerase reverse transcriptase (TERT) hotspot mutations on clinicopathological features, response to treatment, potential recurrence, and the final outcome. Methods: A retrospective analysis of the 430 PTMC cases diagnosed during 2001-2020 at a single center was performed. All PTMC cases were assessed histopathologically, and analyses of BRAFV600E and TERT promoter were performed based on DNA isolated from tumor blocks. Results: There were 29/430 (6.7% [confidence interval: 4.6-9.5]) patients in whom the TERTC228T and/or TERTC250T mutations coexisted with the BRAFV600E mutation. A statistical comparison between PTMC cases with concomitant BRAFV600E and TERT hotspot mutations and those without any of those mutations revealed no significant differences between the two groups with respect to risk stratification, response to primary treatment, clinical course, or final disease status. Conclusion: Regardless of the molecular background of PTMC, the overall response to therapy is excellent, and long-term disease-free survival rates can be achieved by most patients.
引用
- Kuchareczko A, Kopczyński J, Kowalik A, et al. A Significance of Concomitant BRAFV600E and TERT Mutations in Polish Patients with Papillary Thyroid Microcarcinoma: A Retrospective Cohort Study Based on 430 Cases. Thyroid. 2022. PMID: 35950639. doi:10.1089/thy.2022.0155
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。